49 research outputs found
An Observational Case-Control Study on Parental Age and Childhood Renal Tumors.
Despite excellent outcomes, many open questions remain about Wilms tumor (WT). Influences and risk factors for tumorigenesis, as well as tumor aggressiveness and recurrence, are not fully understood. Parental age plays a role in various childhood diseases and is also discussed as a risk factor for childhood cancer. We analyzed both maternal and paternal age at birth as risk factors for the occurrence of Wilms and non-Wilms tumors in children and investigated whether older maternal or paternal age is associated with a higher tumor incidence. During 1990 and 2019 we collected data from 3991 patients from the multicenter studies SIOP9/GPO, SIOP 93-01/GPOH, and SIOP 2001/GPOH, of whom maternal and paternal age was available in 2277 cases. Data from the Federal Statistical Office containing live births in Germany from 1990-2019 served as a comparative database. For maternal age at birth, the control data yielded 22,451,412 cases and for paternal age yielded 19,046,314 cases. Comparing maternal and paternal ages of the study patients with those of the control data, we confirmed that higher parental age is not correlated with the incidence of renal tumors in childhood. Mean ages of fathers and mothers in patients and the control cohort increased between 1991 and 2019 (fathers: 30.28 vs. 34.04; mothers: 27.68 vs. 29.79 in the patient group and 31.29 vs. 34.23 and 28.88 vs. 32.67 in the control group, respectively) without higher numbers of patients with kidney cancer over time. No influence was found for the subtype of cancer nor for syndromes. In addition, overall survival of patients is independent of the year of diagnosis and the age of the parents but depends on histology type and stage in WT
An Observational Case-Control Study on Parental Age and Childhood Renal Tumors
Despite excellent outcomes, many open questions remain about Wilms tumor (WT). Influences and risk factors for tumorigenesis, as well as tumor aggressiveness and recurrence, are
not fully understood. Parental age plays a role in various childhood diseases and is also discussed
as a risk factor for childhood cancer. We analyzed both maternal and paternal age at birth as risk
factors for the occurrence of Wilms and non-Wilms tumors in children and investigated whether
older maternal or paternal age is associated with a higher tumor incidence. During 1990 and 2019 we
collected data from 3991 patients from the multicenter studies SIOP9/GPO, SIOP 93-01/GPOH, and
SIOP 2001/GPOH, of whom maternal and paternal age was available in 2277 cases. Data from the
Federal Statistical Office containing live births in Germany from 1990–2019 served as a comparative
database. For maternal age at birth, the control data yielded 22,451,412 cases and for paternal age
yielded 19,046,314 cases. Comparing maternal and paternal ages of the study patients with those of
the control data, we confirmed that higher parental age is not correlated with the incidence of renal
tumors in childhood. Mean ages of fathers and mothers in patients and the control cohort increased
between 1991 and 2019 (fathers: 30.28 vs. 34.04; mothers: 27.68 vs. 29.79 in the patient group and
31.29 vs. 34.23 and 28.88 vs. 32.67 in the control group, respectively) without higher numbers of
patients with kidney cancer over time. No influence was found for the subtype of cancer nor for
syndromes. In addition, overall survival of patients is independent of the year of diagnosis and the
age of the parents but depends on histology type and stage in WT
Current and emerging therapeutic approaches for extracranial malignant rhabdoid tumors
Extracranial malignant rhabdoid tumors (extracranial MRT) are rare, highly aggressive malignancies affecting mainly infants and children younger than 3 years. Common anatomic sites comprise the kidneys (RTK – rhabdoid tumor of kidney) and other soft tissues (eMRT – extracranial, extrarenal malignant rhabdoid tumor). The genetic origin of these diseases is linked to biallelic pathogenic variants in the genes SMARCB1, or rarely SMARCA4, encoding subunits of the SWI/SNF chromatin-remodeling complex. Even if extracranial MRT seem to be quite homogeneous, recent epigenome analyses reveal a certain degree of epigenetic heterogeneity. Use of intensified therapies has modestly improved survival for extracranial MRT. Patients at standard risk profit from conventional therapies; most high-risk patients still experience a dismal course and often therapy resistance. Discoveries of clinical and molecular hallmarks and the exploration of experimental therapeutic approaches open exciting perspectives for clinical and molecularly stratified experimental treatment approaches. To ultimately improve the outcome of patients with extracranial MRTs, they need to be characterized and stratified clinically and molecularly. High-risk patients need novel therapeutic approaches including selective experimental agents in phase I/II clinical trials
Outcomes of patients with Wilms' tumour stage III due to positive resection margins only: An analysis of patients treated on the SIOP-WT-2001 protocol in the UK-CCLG and GPOH studies.
Stage III Wilms' tumour (WT) represents a heterogeneous group which includes different criteria, but all stage III patients are treated according to the same study regiment. The aim of the study was to retrospectively analyse outcomes in patients with stage III due to positive resection margins (RM) only, sub-grouped in RM with viable (RM-v) and nonviable (RM-nv) tumour. Patients were treated pre- and postoperatively according to the SIOP-WT-2001 protocol in the UK-CCLG and GPOH WT trials and studies (2001-2020). There were 197 patients, including 134 with localised, abdominal stage III and 63 with overall stage IV, but abdominal stage III. Stage III due to RM-v had 126 patients, and due to RM-nv 71 patients. The overall 5-year local-relapse-free survival (RFS), event-free (EFS) and overall survival (OS) estimates for all patients with abdominal stage III RM were 95.7% (±SE1.5%), 85.1 (±SE2.6%) and 90.3% (±SE2.2%), respectively. Patients with stage III RM-nv had significantly better RFS and EFS than patients with RM-v (P = .027 and P = .003, respectively). A multivariate analysis showed that RM-v remained a significant factor for EFS when adjusted for age, presence of metastasis at diagnosis, histological risk group and overall stage in Cox regression analysis (P = .006). Patients with stage III due to RM-nv only exhibited no local recurrence and have a significantly better RFS and EFS than patients with RM-v. The results suggest that exclusion of RM-nv as a stage III criterion in the UMBRELLA staging system and consequent treatment reduction is warranted
Outcomes of patients with Wilms' tumour stage III due to positive resection margins only: An analysis of patients treated on the SIOP-WT-2001 protocol in the UK-CCLG and GPOH studies
Stage III Wilms' tumour (WT) represents a heterogeneous group which includes different criteria, but all stage III patients are treated according to the same study regiment. The aim of the study was to retrospectively analyse outcomes in patients with stage III due to positive resection margins (RM) only, sub-grouped in RM with viable (RM-v) and nonviable (RM-nv) tumour. Patients were treated pre- and postoperatively according to the SIOP-WT-2001 protocol in the UK-CCLG and GPOH WT trials and studies (2001-2020). There were 197 patients, including 134 with localised, abdominal stage III and 63 with overall stage IV, but abdominal stage III. Stage III due to RM-v had 126 patients, and due to RM-nv 71 patients. The overall 5-year local-relapse-free survival (RFS), event-free (EFS) and overall survival (OS) estimates for all patients with abdominal stage III RM were 95.7% (±SE1.5%), 85.1 (±SE2.6%) and 90.3% (±SE2.2%), respectively. Patients with stage III RM-nv had significantly better RFS and EFS than patients with RM-v (P = .027 and P = .003, respectively). A multivariate analysis showed that RM-v remained a significant factor for EFS when adjusted for age, presence of metastasis at diagnosis, histological risk group and overall stage in Cox regression analysis (P = .006). Patients with stage III due to RM-nv only exhibited no local recurrence and have a significantly better RFS and EFS than patients with RM-v. The results suggest that exclusion of RM-nv as a stage III criterion in the UMBRELLA staging system and consequent treatment reduction is warranted
Correction : Welter et al. Characteristics of Nephroblastoma/Nephroblastomatosis in Children with a Clinically Reported Underlying Malformation or Cancer Predisposition Syndrome. Cancers 2021, 13, 5016
In the original article [1] there was a mistake in Table 2 as published. Table 2 contains
wrong percentages in lines Bilateral disease and Patients with CPS or GU. For this reason the
table should be replaced with the correct one as shown belo
Impact of Time to Surgery on Outcome in Wilms Tumor Treated with Preoperative Chemotherapy
(1) Background: Wilms tumor (WT) treated preoperatively is cured in over 90% of cases.
However, how long preoperative chemotherapy can be given is unknown. (2) Methods: 2561/3030 patients with WT (age < 18 years) treated between 1989 and 2022 according to SIOP-9/GPOH, SIOP-93-
01/GPOH, and SIOP-2001/GPOH are retrospectively analyzed to assess the risk of time to surgery
(TTS) for relapse-free survival (RFS) and overall survival (OS). (3) Results: TTS was calculated for
all surgeries, with the mean being 39 days (38.5 ± 12.5) for unilateral tumors (UWT) and 70 days
(69.9 ± 32.7) for bilateral disease (BWT). Relapse occurred in 347 patients, of which 63 (2.5%) were
local, 199 (7.8%) were metastatic, and 85 (3.3%) were combined. Moreover, 184 patients (7.2%) died,
152 (5.9%) due to tumor progression. In UWT, recurrences and mortality are independent of TTS. For
BWT without metastases at diagnosis, the incidence of recurrence is less than 18% up to 120 days
and increases to 29% after 120 days, and to 60% after 150 days. The risk of relapse (Hazard Ratio)
adjusted for age, local stage, and histological risk group increases to 2.87 after 120 days (CI 1.19–7.95,
p = 0.022) and to 4.62 after 150 days (CI 1.17–18.26, p = 0.029). In metastatic BWT, no influence of TTS
is detected. (4) Conclusions: The length of preoperative chemotherapy has no negative impact on
RFS or OS in UWT. In BWT without metastatic disease, surgery should be performed before day 120,
as the risk of recurrence increases significantly thereafter
Characteristics of Nephroblastoma/Nephroblastomatosis in Children with a Clinically Reported Underlying Malformation or Cancer Predisposition Syndrome
(1) Background: about 10% of Wilms Tumor (WT) patients have a malformation or cancer
predisposition syndrome (CPS) with causative germline genetic or epigenetic variants. Knowledge
on CPS is essential for genetic counselling. (2) Methods: this retrospective analysis focused on
2927 consecutive patients with WTs registered between 1989 and 2017 in the SIOP/GPOH studies.
(3) Results: Genitourinary malformations (GU, N = 66, 2.3%), Beckwith-Wiedemann spectrum
(BWS, N = 32, 1.1%), isolated hemihypertrophy (IHH, N = 29, 1.0%), Denys-Drash syndrome (DDS,
N = 24, 0.8%) and WAGR syndrome (N = 20, 0.7%) were reported most frequently. Compared to
others, these patients were younger at WT diagnosis (median age 24.5 months vs. 39.0 months),
had smaller tumors (349.4 mL vs. 487.5 mL), less often metastasis (8.2% vs. 18%), but more often
nephroblastomatosis (12.9% vs. 1.9%). WT with IHH was associated with blastemal WT and DDS
with stromal subtype. Bilateral WTs were common in WAGR (30%), DDS (29%) and BWS (31%).
Chemotherapy induced reduction in tumor volume was poor in DDS (0.4% increase) and favorable
in BWS (86.9% reduction). The event-free survival (EFS) of patients with BWS was significantly
(p = 0.002) worse than in others. (4) Conclusions: CPS should be considered in WTs with specific
clinical features resulting in referral to a geneticist. Their outcome was not always favorable
Vena Cava Thrombus in Patients with Wilms Tumor
(1) Background: Vena cava thrombus (VCT) is rare in Wilms tumor (WT) (4–10%). The aim
of this study is to identify factors for an outcome to improve treatment for better survival. (2) Methods:
148/3015 patients with WT (aged < 18 years) and VCT, prospectively enrolled over a period of 32
years (1989–2020) by the German Society for Pediatric Oncology and Hematology (SIOP-9/GPOH,
SIOP-93-01/GPOH and SIOP-2001/GPOH), are retrospectively analyzed to describe clinical features,
response to preoperative chemotherapy (PC) (142 patients) and surgical interventions and to evaluate
risk factors for overall survival (OS). (3) Results: 14 VCT regressed completely with PC and another
12 in parts. The thrombus was completely removed in 111 (85.4%), incompletely in 16 (12.3%), and
not removed in 3 (2.3%). The type of removal is unknown in four patients. Patients without VCT
have a significantly (p < 0.001) better OS (97.8%) than those with VCT (90.1%). OS after complete
resection is (89.9%), after incomplete (93.8%) and with no resection (100%). Patients with anaplasia or
stage IV without complete remission (CR) after PC had a significantly worse OS compared to the
remaining patients with VCT (77.1% vs. 94.4%; p = 0.002). (4) Conclusions: As a result of our study,
two risk factors for poor outcomes in WT patients with VCT emerge: diffuse anaplasia and metastatic
disease, especially those with non-CR after PC
Impact of Time to Surgery on Outcome in Wilms Tumor Treated with Preoperative Chemotherapy
(1) Background: Wilms tumor (WT) treated preoperatively is cured in over 90% of cases. However, how long preoperative chemotherapy can be given is unknown.
(2) Methods: 2561/3030 patients with WT (age < 18 years) treated between 1989 and 2022 according to SIOP-9/GPOH, SIOP-93-01/GPOH, and SIOP-2001/GPOH are retrospectively analyzed to assess the risk of time to surgery (TTS) for relapse-free survival (RFS) and overall survival (OS).
(3) Results: TTS was calculated for all surgeries, with the mean being 39 days (38.5 ± 12.5) for unilateral tumors (UWT) and 70 days (69.9 ± 32.7) for bilateral disease (BWT). Relapse occurred in 347 patients, of which 63 (2.5%) were local, 199 (7.8%) were metastatic, and 85 (3.3%) were combined. Moreover, 184 patients (7.2%) died, 152 (5.9%) due to tumor progression. In UWT, recurrences and mortality are independent of TTS. For BWT without metastases at diagnosis, the incidence of recurrence is less than 18% up to 120 days and increases to 29% after 120 days, and to 60% after 150 days. The risk of relapse (Hazard Ratio) adjusted for age, local stage, and histological risk group increases to 2.87 after 120 days (CI 1.19-7.95, p = 0.022) and to 4.62 after 150 days (CI 1.17-18.26, p = 0.029). In metastatic BWT, no influence of TTS is detected.
(4) Conclusions: The length of preoperative chemotherapy has no negative impact on RFS or OS in UWT. In BWT without metastatic disease, surgery should be performed before day 120, as the risk of recurrence increases significantly thereafter